NCT02454010View on ClinicalTrials.gov

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Solid Tumor
Interventions
BIOLOGICAL

FF21101

(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Trial Locations (4)

30322

Winship Cancer Institute - Emory University, Atlanta

60611

Northwestern University - Feinberg School of Medicine, Chicago

73104

Stephenson Cancer Center, Oklahoma City

77030

University of Texas M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Fujifilm Pharmaceuticals U.S.A., Inc.

INDUSTRY